Navigation Links
ETEX Corporation to present at the 9th World Biomaterial Congress
Date:5/22/2012

CAMBRIDGE, Mass., May 22, 2012 /PRNewswire/ -- ETEX Corporation, an advanced biomaterials company, today announced two presentations at the upcoming 9th World Biomaterial Congress, June 1-5, 2012 in Chengdu, China. ETEX will highlight their vertebral augmentation and cell carrier development programs.

Dr. Jerry Chang, Head of R&D of ETEX Corporation, will deliver an oral presentation entitled "Enhanced Calcium Phosphate Cements for Vertebral Augmentation" during Rapid Fire Session (R3), June 3rd 2012. Dr. Chang will highlight an injectable Calcium Phosphate scaffold with superior cancellous bone filling, hard setting, and cell mediated remodeling for bone regeneration in vertebral compression fracture repair applications.

ETEX Corporation scientific team will also showcase recent advancements in their Stem Cell Carrier program during the poster session (R1).  The presentation is entitled "Calcium Phosphate Combination Biomaterials as Human Mesenchymal Stem Cell (hMSC) Delivery Vehicles for Bone Repair." This marks ETEX's third presentation regarding their cell carrier platform in the last six months, following oral presentations at the 4th Annual World Congress of Regenerative Medicine & Stem Cell in Beijing, China, and the GTC 8th Stem Cell Summit in Boston, MA.

As a pioneer in implantable biomaterials and the delivery of orthobiologics, such as growth factors and cells, ETEX is excited to participate in this important event.

Brian Ennis, President and CEO of ETEX Corporation, comments: "ETEX is eager to highlight two important development platforms at the upcoming World Biomaterial Congress in Chengdu. The setting is particularly relevant as ETEX is collaborating with leading centers in China to further document the clinical efficacy of ETEX biomaterials. This collaborative initiative will result in additional clinical documentation and lead to commercialization of our leading orthobiologic platforms in the rapidly expanding Chinese orthopedic market."

About ETEX Corporation

Established in 1989, ETEX Corporation develops, manufactures and commercializes calcium phosphate-based biomaterials for improved orthopedic clinical outcomes. A leader in bioresorbable bone substitute materials, ETEX focuses on expanding applications through combinations with cells, biologics, or therapeutic agents delivered in minimally invasive and easy to use systems. For more information, visit www.etexcorp.com.


'/>"/>
SOURCE ETEX Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Sigma-Aldrich Corporation Announces New Credit Facility
2. Verenium Corporation To Announce First Quarter 2012 Financial Results
3. China Cord Blood Corporation Announces Completion of $65 Million Convertible Debt Financing with KKR
4. Luminex Corporation Receives CE Mark for Revolutionary Newborn Screening Platform
5. ETEX Corporation to Present at GTC Stem Cell Summit
6. Psyche Systems Corporation Signs Strategic Alliance with Siemens Healthcare to Provide Anatomic Pathology Solutions
7. Hamamatsu Corporation Announces Exclusive Distribution of Its NanoZoomer Whole-Slide Scanners
8. Luminex Corporation to Speak at Joint Department of Defense and Environmental Protection Agency 5th National Bio-Threat Conference
9. Verenium Corporation to Announce Fourth Quarter and Year-End 2011 Financial Results
10. China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2012
11. JBT Corporation and Swisslog Enter Into Partnership for Automated Guided Vehicles
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... ... February 23, 2017 , ... The Greater Gift Initiative, Inc , ... Compass Research . GGI's mission is to advance global health and highlight the ... need in honor of each clinical trial volunteer. The vision of GGI is to ...
(Date:2/23/2017)... SAN FRANCISCO , Feb. 23, 2017 /PRNewswire/ ... and Beyond Type 1, a not-for-profit advocacy and education ... announced a grant from Beyond Type 1 to support ... 1 and other insulin-requiring diabetes.  For ... stem cell-derived cell replacement therapies with a focus on ...
(Date:2/22/2017)... , ... February 22, 2017 , ... ... is has acquired Kendall Research Systems, LLC (KRS) clinical development program. ... develops neural interface technology for research and clinical applications. The terms of the ...
(Date:2/22/2017)... CINCINNATI , Feb. 22, 2017 Scientists ... drives inflammation and organ damage in Gaucher and maybe ... fewer risks and lower costs than current therapies. ... Children,s Hospital Medical Center , which also included investigators ... , report their data Feb. 22. The study ...
Breaking Biology Technology:
(Date:2/8/2017)... Mass., Feb. 7, 2017  Aware, Inc. (NASDAQ: ... today reported financial results for its quarter and year ended ... quarter of 2016 was $3.9 million compared to $6.9 million ... fourth quarter of 2016 was $0.6 million compared to $2.6 ... the fourth quarter of 2016 was $0.5 million, or $0.02 ...
(Date:2/8/2017)... , Feb. 7, 2017 Report Highlights ... billion by 2021 from $8.3 billion in 2016 at ... 2016 to 2021. Report Includes - An overview ... global market trends, with data from 2015 and 2016, ... 2021. - Segmentation of the market on the basis ...
(Date:2/7/2017)... York , February 7, 2017 ... ID Global Solutions Corporation [OTC: IDGS], ("Ipsidy" or the ... and electronic transaction processing services, is pleased to announce ... the Company. Effective January 31, 2017, ... Board of Directors, CEO and President.  An experienced payment ...
Breaking Biology News(10 mins):